Patients, Personnel, And Personalities: How These Three "P"s Are Driving Rx Access Debates
Regulatory personnel prepare policies to help patients. Sometimes patients push for policies. Regardless of your perspective, it's clear that personalities can drive shifts in prescription oversight – and even reimbursement, as recent news in the US suggests. This week, the Pink Sheet's LinkedIn newsletter brings you stories on management philosophy and Rx pricing, all brought to you by the letter P.
Why’s it important?
Finalized EU pharmaceutical legislation must ensure that patients are fairly represented in regulatory decision-making, according to patient and industry experts.
Why’s it important?
New promotions and social media posts may offer some hints as to the philosophies guiding agency leaders. One CBER appointee stands out for her connections to Arnold Ventures.
Why’s it important?
FDA’s former CBER director is joining industry as senior VP of molecule discovery and head, infectious disease at Eli Lilly.
Why’s it important?
CMS Administrator Oz punted on a GLP-1 question in an interview, suggesting it was because his agency will be acting soon.
Start a one-week free trial at Citeline News & Insights!
Why’s it important?
Marty Makary's role in helping negotiate the Trump Administration's second "most favored nations" drug pricing deal is raising concerns, as the Trump team has suggested it would use drug pricing as a lever to impact FDA approval status or speed of drug reviews.
Want full access to Citeline News & Insights? Start your one-week free trial today!